FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

FDA experts discuss the first approval of a cancer treatment based on a common biomarker rather primary tumor location.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free